Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss health-care firm Roche is planning to invest CHF3bn ($3.2bn) over the next ten years on development work at its Basel site, including CHF1.7bn ($1.8bn) on the construction of a new research and development (R&D) centre.
Subscribe to our email newsletter
The new research centre, which will include four integrated office/laboratory buildings of different heights, will house around 1900 workplaces and is scheduled to be completed between 2021 and 2022.
Apart from the R&D centre, the company will also construct a new office building for up to 1700 employees and upgrade existing infrastructure.
The new R&D centre is designed to facilitate communication and further strengthen teamwork among research staff.
Roche CEO Severin Schwan said the company is committed long-term to Switzerland and to Basel in its dual role as corporate headquarters and one of its most important sites worldwide.
"The entire value chain is represented in Basel. Employees from all parts of the company are making a vital contribution to Roche’s innovative strength, and we want to provide them with an attractive work environment," Schwan said.
"The new buildings will continue Roche’s tradition of elegant, distinctive and functional architecture."
Additionally, an in vivo research facility is being built, which is scheduled for completion by the end of 2018.